Gene-modified T cell therapy for refractory acute myeloid leukemia harboring a FLT3/ITD mutation

2016 Fiscal Year Final Research Report

• Project/Area Number: 26461574
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Pediatrics
• Research Institution: Shinshu University
• Principal Investigator: NAKAZAWA Yozo 信州大学, 学術研究院医学系, 教授 (60397312)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: キメラ抗原受容体 / T細胞療法 / がん免疫療法 / 急性骨髄性白血病

Outline of Final Research Achievements

Patients with FLT3/ITD-mutated acute myeloid leukemia (AML) have a poor prognosis. A FLT3/ITD-mutated AML cell line, MV4-11, highly express GM-CSF receptors (GMR). We developed T cells engineered to express a chimeric antigen receptor (CAR) targeting the GMR. GMR CAR T cells eliminated MV4-11 cells up to 98% after a 5 days-coculture at a T cells: leukemia cells ratio of 1:5. Adoptive immunotherapy using GMR CAR T cells may a promising option for AML harboring a FLT3/ITD mutation.

Free Research Field

小児血液学